Cargando…
Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer
Decay-accelerating factor (CD55 or DAF) inhibits complement-dependent cytotoxicity. We determined that CD55 is overexpressed in 76.47% of human non-small cell lung cancer tissue specimens. We therefore developed a lutetium-177-labeled chimeric monoclonal antibody against CD55. CD55-specific single-c...
Autores principales: | Dho, So Hee, Kim, Soo Yong, Chung, Chaeuk, Cho, Eun Ha, Lee, So-Young, Kim, Ji Young, Kim, Lark Kyun, Min, Sung-Won, Lee, Jichul, Jung, Sung Hee, Lim, Jae Cheong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997699/ https://www.ncbi.nlm.nih.gov/pubmed/29895866 http://dx.doi.org/10.1038/s41598-018-27355-8 |
Ejemplares similares
-
Beyond the Role of CD55 as a Complement Component
por: Dho, So Hee, et al.
Publicado: (2018) -
Subcellular Targeting of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2018) -
Hypermethylation of PDX1, EN2, and MSX1 predicts the prognosis of colorectal cancer
por: Lee, Yeongun, et al.
Publicado: (2022) -
NOX5-L can stimulate proliferation and apoptosis depending on its levels and cellular context, determining cancer cell susceptibility to cisplatin
por: Dho, So Hee, et al.
Publicado: (2015) -
Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)